"It is unacceptable that a company of this size and which has recently also benefited from strong economic revenues should proceed with personnel reductions". The voice of Thomas Borromeo, secretary general of the Filctem CGIL of Siena, is the voice of all the unions, united in contesting the recent decision by Novartis to send 20 out of 27 pharmaceutical informers and four employees of the sales network into redundancy, just as the scandal of the 184 million euro spent unnecessarily by the Ministry of Health to ensure the supply of vaccines against the flu pandemic.
A maxi order, sanctioned by a sort of halter contract, which has allowed the pharmaceutical company to increase its profits but which has not brought as many benefits to the workers, since the 527 new employees recruited for the extraordinary production of the vaccine are were all hired on temporary contracts.
However, Novartis defends itself. He argues that the reorganization is justified by the fact that today, for the sale of vaccines, it is negotiated with the ASL and the Regions and therefore there is no longer a need to have a certain number of informants to convince pediatricians and general practitioners. What credibility do these motivations have? None, for a simple fact. The other competing companies have them all in their commercial network at least from 35 to 40 employees. After this one reorganization, Novartis would remain
